336 related articles for article (PubMed ID: 12904990)
1. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
[TBL] [Abstract][Full Text] [Related]
2. [Role of matrix metalloproteinases-9, 2 and their inhibitor-TIMP-1, 2 in invasive pituitary adenomas biological behavior].
He DS; Chen MZ; Wang HJ; Ke CL; Yan C; Zheng H; Hong YS
Ai Zheng; 2002 Oct; 21(10):1124-8. PubMed ID: 12508658
[TBL] [Abstract][Full Text] [Related]
3. [Expression of MMPPs and TIMP and invasiveness in pituitary adenomas].
Wang J; Liu YS
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):647-50. PubMed ID: 16114548
[TBL] [Abstract][Full Text] [Related]
4. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
5. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas.
Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S
J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
8. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
Emenaker NJ; Basson MD
J Surg Res; 1998 Apr; 76(1):41-6. PubMed ID: 9695737
[TBL] [Abstract][Full Text] [Related]
9. Expression and localisation of extracellular matrix degrading proteases and their inhibitors during the oestrous cycle and after induced luteolysis in the bovine corpus luteum.
Kliem H; Welter H; Kraetzl WD; Steffl M; Meyer HH; Schams D; Berisha B
Reproduction; 2007 Sep; 134(3):535-47. PubMed ID: 17709571
[TBL] [Abstract][Full Text] [Related]
10. Progress of tissue injury in appendicitis involves the serine proteases uPA and PAI-1.
Solberg A; Holmdahl L; Falk P; Willén R; Palmgren I; Ivarsson ML
Scand J Gastroenterol; 2009; 44(5):579-84. PubMed ID: 19153874
[TBL] [Abstract][Full Text] [Related]
11. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
12. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
[TBL] [Abstract][Full Text] [Related]
13. Brain-derived neurotrophic factor inducing angiogenesis through modulation of matrix-degrading proteases.
Sun CY; Hu Y; Wang HF; He WJ; Wang YD; Wu T
Chin Med J (Engl); 2006 Apr; 119(7):589-95. PubMed ID: 16620701
[TBL] [Abstract][Full Text] [Related]
14. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
Pawlak K; Pawlak D; Myśliwiec M
Thromb Res; 2008; 121(4):543-8. PubMed ID: 17706748
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.
Harvey SR; Hurd TC; Markus G; Martinick MI; Penetrante RM; Tan D; Venkataraman P; DeSouza N; Sait SN; Driscoll DL; Gibbs JF
Clin Cancer Res; 2003 Oct; 9(13):4935-43. PubMed ID: 14581368
[TBL] [Abstract][Full Text] [Related]
17. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
[TBL] [Abstract][Full Text] [Related]
18. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
19. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
Park MJ; Lee JY; Kwak HJ; Park CM; Lee HC; Woo SH; Jin HO; Han CJ; An S; Lee SH; Chung HY; Park IC; Hong SI; Rhee CH
J Cell Biochem; 2005 Aug; 95(5):955-69. PubMed ID: 15962302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
